LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/FDA Clears Novel Extremity Implant From Utah Start-Up
Company News

FDA Clears Novel Extremity Implant From Utah Start-Up

March 28, 2017 1 min read Premium comments

Advertisement

FDA Clears Novel Extremity Implant From Utah Start-Up
Source: Wikimedia Commons and Ladyde12
Secondary

Logan, Utah-based extremity implant company, First Ray, hit a key milestone when the FDA gave the firm a 510(k) clearance for additional implants for its innovative Stealth Staple System.

First Ray, a start-up medical device company, designs and is bringing to market mini-implants which target the smaller joints in the body. For example, First Ray’s implants are indicated for hindfoot fusions, first tarsometatarsal joint fusions, midfoot fusion, first metatarsophalangeal fusions and carpal fusions.

The company’s mini size implants were designed for carpometacarpal joint fusions, lesser metatarsophalangeal fusions, and fixation of Akin osteotomies.

First Ray’s mini implants are made from titanium alloy and the more standard sizes come in PEEK (Polyetheretherketone).

According to the company’s press release, the Stealth Staple System is “an intraosseous small bone fixation system used to treat arthrodesis, osteotomies and bone fractures.”

First Ray claims that because the system is entirely embedded in the bone and there is “controlled and evenly distributed compression across the opposing bone surfaces”, the risk for complications is greatly reduced.

First Ray is incubated and operated by Surgical Frontiers, LLC, a financial and investment services company that specializes in medical devices.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy